Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits

Atherosclerosis

Volumn 218, Issue 2, 2011, Pages 300-307

  Iwata, Atsushi ^a   Miura, Shin Ichiro ^a   Zhang, Bo ^a   Imaizumi, Satoshi ^a   Uehara, Yoshinari ^a   Shiomi, Masashi ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apolipoprotein a i mimetic peptide; Capillary isotachophoresis; Cholesterol efflux; Intravascular ultrasound; Plaque; Watanabe heritable hyperlipidemic rabbits

Indexed keywords

2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; APOLIPOPROTEIN A1; CARDIOVASCULAR AGENT; CHOLESTEROL; ETC 642; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEPTIDOMIMETIC AGENT; PHOSPHOLIPID; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIATHEROGENIC EFFECT; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CAPILLARY ELECTROPHORESIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR PARAMETERS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; EXPERIMENTAL RABBIT; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; INTRAVASCULAR ULTRASOUND; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MACROPHAGE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; ULTRACENTRIFUGATION;

ANIMALS; AORTA; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CHOLESTEROL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; HYPERLIPIDEMIAS; ISOTACHOPHORESIS; LIPOPROTEINS, LDL; PEPTIDES; PLACEBOS; RABBITS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 80053261614     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.05.029     Document Type: Article

References (27)

1. von Eckardstein A., Nofer J.R., Assmann G. Acceleration of reverse cholesterol transport. Curr Opin Cardiol 2000, 15:348-354.
2. Gordon D.J., Rifkind B.M. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989, 321:1311-1336.
3. Parolini C., Marchesi M., Lorenzon P., et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol 2008, 51:1098-1103.
4. Ibanez B., Vilahur G., Cimmino G., et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol 2008, 51:1104-1109.
5. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc 2003, 290:2292-2300.
6. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006, 47:992-997.
7. Navab M., Anantharamaiah G.M., Hama S., et al. Oral administration of an ApoA-I mimetic peptide synthesized from d-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002, 105:290-292.
8. Li X., Chyu K.Y., Faria Neto J.R., et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004, 110:1701-1705.
9. Remaley A.T., Thomas F., Stonik J.A., et al. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 2003, 44:828-836.
10. Shiomi M., Ito T., Yamada S., Kawashima S., Fan J. Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). Arterioscler Thromb Vasc Biol 2003, 23:1239-1244.
11. Iwata A., Miura S., Imaizumi S., Zhang B., Saku K. Measurement of atherosclerotic plaque volume in hyperlipidemic rabbit aorta by intravascular ultrasound. J Cardiol 2007, 50:229-234.
12. Imaizumi S., Miura S., Nakamura K., et al. Antiarrhythmogenic effect of reconstituted high-density lipoprotein against ischemia/reperfusion in rats. J Am Coll Cardiol 2008, 51:1604-1612.
13. Rye K.A., Garrety K.H., Barter P.J. Changes in the size of reconstituted high density lipoproteins during incubation with cholesteryl ester transfer protein: the role of apolipoproteins. J Lipid Res 1992, 33:215-224.
14. Böttcher A., Schlosser J., Kronenberg F., et al. Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: apolipoprotein and lipid composition of HDL subfractions. J Lipid Res 2000, 41:905-915.
15. Zhang B., Uehara Y., Hida S., et al. Effects of reconstituted HDL on charge-based LDL subfractions as characterized by capillary isotachophoresis. J Lipid Res 2007, 48:1175-1189.
16. Zhang B., Kaneshi T., Ohta T., Saku K. Relation between insulin resistance and fast-migrating LDL subfraction as characterized by capillary isotachophoresis. J Lipid Res 2005, 46:2265-2277.
17. Chiesa G., Parolini C., Sirtori C.R. Acute effects of high-density lipoproteins: biochemical basis and clinical findings. Curr Opin Cardiol 2008, 23:379-385.
18. Khan M., Lalwani N.D., Drake S.L., Crokatt J.G., Dasseux J.H. Single-dose intravenous infusion of ETC-642, a 22-mer apoA-I analogue and phospholipid complex, elevates HDL-C in atherosclerosis patients. Circulation 2003, 108(Suppl. IV):563-564.
19. Nanjee M.N., Doran J.E., Lerch P.G., Miller N.E. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol 1999, 19:979-989.
20. Nishimaki-Mogami T., Suzuki K., Takahashi A. The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing lipoproteins. Biochim Biophys Acta 1996, 1304:21-31.
21. Park T.S., Panek R.L., Mueller S.B., et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004, 110:3465-3471.
22. Shiomi M., Ito T. The Watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of development: a tribute to the late Dr Yoshio Watanabe. Atherosclerosis 2009, 207:1-7.
23. Shah P.K., Chyu K.Y. Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends Cardiovasc Med 2005, 15:291-296.
24. Chiesa G., Monteggia E., Marchesi M., et al. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002, 90:974-980.
25. Chiesa G., Di Mario C., Colombo N., et al. Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound. Atherosclerosis 2001, 156:277-287.
26. Kragel A.H., Reddy S.G., Wittes J.T., Roberts W.C. Morphometric analysis of the composition of coronary arterial plaques in isolated unstable angina pectoris with pain at rest. Am J Cardiol 1990, 66:562-567.
27. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). Atherosclerosis 1980, 36:261-268.